U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07399730) titled 'Ravulizumab Outcomes in Polish Patients With aHUS' on Jan. 27.
Brief Summary: This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).
Study Start Date: April 01
Study Type: OBSERVATIONAL
Condition:
Atypical Hemolytic Uremic Syndrome
Intervention:
DRUG: Ravulizumab
Ultomiris
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Astra...